Endpoints News Jan 8, 2026 FDA staff cuts mostly didn't impact new drug review timelines, analysis finds
Endpoints News Jan 8, 2026 Ollin’s drug clears retinal disease better than Roche’s Vabysmo in Phase 1b trial
Endpoints News Jan 8, 2026 French biotech Enodia gets €20.7M aided by Pfizer for protein degrader work
Endpoints News Jan 8, 2026 Charles Fuchs leaves Roche to steer ADC pipeline at Tubulis shortly after $401M Series C
Endpoints News Jan 8, 2026 Former Genentech leaders’ protein degrader startup EpiBiologics nets $107M
Endpoints News Jan 7, 2026 Immuneering’s pancreatic cancer pill continues to beat standard care, updated first line data show